AzTrials
AzTrials

Parkinson DiseasePhase 4TANDEM-569NCT01494532

A Fixed Dose Study of Ropinirole Prolonged Release as Adjunctive Treatment in Patients With Advanced Parkinson's Disease

A Phase 4 study testing ropinirole/L-dopa in people with Parkinson Disease, run by GlaxoSmithKline at 52 sites in 7 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a double blind, fixed dose, parallel group study to characterize the dose response of ropinirole PR as adjunctive therapy to L-dopa in patients with late stage Parkinson's disease. Read more about this study

Who is it for?
Ages 30 years and older
Conditions the study is for
Parkinson Disease
What is being tested?
ropinirole/L-dopa
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
352 participants
Where
52 sitesin 7 countries
Study dates
2 Apr 2012to 18 Nov 2014
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of idiopathic Parkinson's disease (according to modified Hoehn \& Yahr criteria Stages II-IV) and demonstrating lack of control with L-dopa therapy (e.g.
  • end of dose akinesia, simple on/off fluctuations).
  • Subjects receiving a stable dose of L-dopa for at least 4 weeks prior to screening.
  • A minimum of 3 hours awake "off-time" for each diary day recorded during the baseline period.
  • Men or non-pregnant/non-breast-feeding women of at least 30 years of age at screening. Women of child-bearing potential must be practicing a clinically accepted method of contraception during the study and for at least one month prior to randomization and one month following completion of the study. Acceptable contraceptive methods include abstinence, oral contraception, injectable progestogen, implants of levonorgestrel, estrogenic vaginal ring, percutaneous contraceptive patches, surgical sterilisation, male partner sterilization, intrauterine device [IUD], or double barrier method: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal agent (foam/gel/film/cream/suppository.
  • Provide written informed consent for this study.
  • Be willing and able to comply with study procedures, including diary card completion and follow-up clinic visits.

Who cannot join

  • Late stage advanced subjects demonstrating incapacitating peak dose or diphasic dyskinesia on their stable dose of L-dopa
  • Consumption of any dopamine agonist, including ropinirole, within four weeks of randomization in the study.
  • Subjects with severe, clinically significant condition(s) other than Parkinson's disease which, in the opinion of the investigator, would render the subject unsuitable for the study (e.g., psychiatric, haematological, renal, hepatic, endocrinology, neurological [other than Parkinson's disease], cardiovascular, or active malignancy [other than basal cell carcinoma]).
  • Subjects with crippling degenerative arthritis or other physical or mental conditions which would preclude accurate assessment of efficacy or safety.
  • Subjects with prior or current major psychosis (e.g., schizophrenia or psychotic depression) e.g. scoring 3 or 4 on UPDRS item 2 [thought disorder] or item 3 [depression].
  • Subjects with severe clinical dementia e.g. scoring 3 or 4 on UPDRS item 1 [mentation].
Show all 16Show fewer
  • Subjects with severe dizziness or fainting due to postural hypotension on standing.
  • Subjects with a personal history of melanoma.
  • Subjects with clinically significant abnormalities in laboratory or ECG tests at Screening. If findings are outside the normal range and the subject is included, it must be documented by the investigator that the findings are not of clinical significance.
  • Subjects who are diagnosed with an impulse control disorder. The modified MIDI will be conducted at screening. Subjects who score positive for this screen must be referred to a specialist for diagnostic evaluation.
  • Subjects who have an active suicidal plan/intent or have had active suicidal thoughts in the past 6 months. Subjects who have a history of suicide attempt in the last 2 years or more than 1 lifetime suicide attempt.
  • Current alcohol or drug dependence.
  • Definite or suspected personal or family history of clinically significant adverse reactions or hypersensitivity to ropinirole (or to drugs with a similar chemical structure) that would preclude long-term dosing with ropinirole.
  • Withdrawal, introduction, or change in dose of hormone replacement therapy and/or any drug known to substantially inhibit CYP1A2 (e.g. ciprofloxacine, fluvoxamine, cimetidine, ethinyloestradiol) or induce CYP1A2 (e.g. tobacco, omeprazole) within 7 days prior to enrolment (randomization). Subjects already on chronic therapy with any of these agents may be enrolled but doses must have remained stable from 7 days prior to enrolment (randomization) through the end of the treatment period.
  • Women who are pregnant or breast-feeding.
  • Use of an investigational drug from 30 days or 5 half-lives (whichever is longer) prior to enrolment (randomization) through to the end of the treatment period. 15. Women who are pregnant or breast-feeding. 16. Use of an investigational drug from 30 days or 5 half-lives (whichever is longer) prior to enrolment (randomization) through to the end of the treatment period.

Trial locations and contacts

52 sites in 7 countries.

52 sites in 7 countries

Russia13 sites
  • GSK Investigational Site

    Chelyabinsk, 454136

  • GSK Investigational Site

    Kazan', 420012

  • GSK Investigational Site

    Krasnoyarsk, 660022

  • GSK Investigational Site

    Kursk, 305007

  • GSK Investigational Site

    Novosibirsk, 630091

  • GSK Investigational Site

    Omsk, 644033

  • GSK Investigational Site

    Perm, 614990

  • GSK Investigational Site

    Saint Petersburg, 194044

  • GSK Investigational Site

    Saratov, 410012

  • GSK Investigational Site

    Smolensk, 214019

  • GSK Investigational Site

    Ufa, 450000

  • GSK Investigational Site

    Yaroslavl, 150030

  • GSK Investigational Site

    Yekaterinburg, 620102

Other trials in Russia

United States9 sites
  • GSK Investigational Site

    Boca Raton, Florida, 33486

  • GSK Investigational Site

    Forest Hills, New York, 11375

  • GSK Investigational Site

    Fountain Valley, California, 92708

  • GSK Investigational Site

    Pasadena, California, 91105

  • GSK Investigational Site

    Reseda, California, 91355

  • GSK Investigational Site

    Richmond, Virginia, 23249

  • GSK Investigational Site

    Springfield, Massachusetts, 01104

  • GSK Investigational Site

    Tampa, Florida, 33612

  • GSK Investigational Site

    Ventura, California, 93003

Other trials in United States

Argentina8 sites
  • GSK Investigational Site

    Buenos Aires, B1602DBG

  • GSK Investigational Site

    Buenos Aires, C1133AAW

  • GSK Investigational Site

    Buenos Aires, C1426AHA

  • GSK Investigational Site

    Caba, 1209

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1200AAT

  • GSK Investigational Site

    Ciudad Autonoma de Buenos Aires, Buenos Aires, C1419AHN

  • GSK Investigational Site

    Ciudad Autónoma de Buenos Aires, Buenos Aires, C1192AAW

  • GSK Investigational Site

    San Martín, Buenos Aires, 1650

Other trials in Argentina

South Korea8 sites
  • GSK Investigational Site

    Anyang-si, 431-070

  • GSK Investigational Site

    Busan, 602-715

  • GSK Investigational Site

    Daejeon, 371718

  • GSK Investigational Site

    Seongnam-si Gyeonggi-do, 463-707

  • GSK Investigational Site

    Seoul, 130-702

  • GSK Investigational Site

    Seoul, 138-736

  • GSK Investigational Site

    Seoul, 152-703

  • GSK Investigational Site

    Sungnam, 463712

Other trials in South Korea

Slovakia7 sites
  • GSK Investigational Site

    Banská Bystrica, 974 04

  • GSK Investigational Site

    Bratislava, 813 69

  • GSK Investigational Site

    Bratislava, 826 06

  • GSK Investigational Site

    Bratislava, 831 03

  • GSK Investigational Site

    Bratislava, 833 05

  • GSK Investigational Site

    Dubnica nad Váhom, 1841

  • GSK Investigational Site

    Trnava, 91702

Other trials in Slovakia

Chile5 sites
  • GSK Investigational Site

    Santiago, 7500551

  • GSK Investigational Site

    Santiago, 7500710

  • GSK Investigational Site

    Santiago, 8260094

  • GSK Investigational Site

    Valdivia, Los Lagos Region, 5090145

  • GSK Investigational Site

    Viña del Mar, Valparaiso, 2570017

Other trials in Chile

Estonia2 sites
  • GSK Investigational Site

    Tallinn, 10138

  • GSK Investigational Site

    Tallinn, 10617

Other trials in Estonia

About this study

Official title: A Fixed Dose, Dose-response Study of Ropinirole Prolonged Release (PR) as Adjunctive Treatment to L-dopa in Patients With Advanced Parkinson's Disease

This is a double blind, fixed dose, parallel group study to characterize the dose response of ropinirole PR as adjunctive therapy to L-dopa in patients with late stage Parkinson's disease. The primary endpoint of this study, mean change from baseline in total awake time spent "off' is the same endpoint as used in the ropinirole PR pivotal study for advanced Parkinson's disease patients. This study includes a wide range of ropinirole doses (4-24mg) with the 8mg, 12mg, and 16mg per day doses powered to detect a 1.7 hour difference in total awake time spent "off" compared with placebo. The dose of Ldopa will remain stable through the study, unless the subject experiences tolerability issues that require an L-dopa dose reduction. Up to three L-dopa dose reductions are allowed, making a total reduction of up to approximately 30%. Keeping the L-dopa dose constant where possible is important to avoid confounding the efficacy data. Clinical review of the primary and secondary endpoints will be performed in order to establish the lowest maximally effective therapeutic dose.

Being tested
ropinirole/L-dopa, placebo/L-dopa
Medical subject headings
Parkinson Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ropinirole/L-dopaDrug

    Ropinirole as adjunctive therapy with L-dopa

  • placebo/L-dopaDrug

    Placebo as adjunctive therapy with L-dopa

Study groups in NCT01494532
Study groupRoleWhat they receive
ropiniroleExperimentalactive treatment 4, 8, 12, 16, or 24mg/day
Receives: Drug: ropinirole/L-dopa
placeboPlacebo comparatorplacebo comparator 4, 8, 12, 16, or 24mg/day
Receives: Drug: placebo/L-dopa

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline (BL) in Total Awake Time Spent "Off" at Week 4 of Maintenance Period

    "Off" time is defined as the state in which the participants(par) symptoms include lack of mobility(bradykinesia) with or without additional features such as tremor or rigidity. Par were asked to record awake time "off ", awake time "on", troublesome dyskinesias(TD) during awake time "on", or time asleep for 30 minute intervals in 24 hr diary cards for 2 days preceding visits. Total number of awake hrs spent "off" per 24-hr period was the average of the 2 diary cards of the sum of awake hours spent "off" in each 24-hr diary card. BL is the last non-missing assessment measured on or before the first dose, change from BL was calculated by subtracting the BL values from the MP Week 4 values. Mixed Model Repeated Measures (MMRM) model used BL total awake time 'Off', treatment, visit and treatment by visit

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

Secondary outcomes (23)
  1. Responder Rate Defined as the Percentage of Participants With a 20% Reduction in Baseline (BL) "Off" Time at Week-4 of Maintenance Period

    The responder rate was defined as the percentage of par with greater than or equal to (>=) 20 percent (%) reduction in their individual BL "off" time at Week 4 of the Maintenance Period. The "off" time is defined as the state in which the participants' symptoms include lack of mobility (bradykinesia) with or without additional features such as tremor or rigidity. BL is defined as the last non-missing assessment measured on or before the first dose date. Responder Rate (Least Squares [LS] means on inverse linked scale), odds ratio with 95% CI and p-value comparing against placebo were estimated by Generalized Estimating Equations (GEE) model. Baseline total awake time 'Off', treatment, visit and treatment*visit are included in the model.

    Measured: Week 4 of the Maintenance Period (Study Week 17)

  2. Percentage of Participants With a >=1 Hour Reduction in Baseline "Off" Time at Week 4 of the Maintenance Period

    The "off" time is defined as the state in which the participants' symptoms include lack of mobility (bradykinesia) with or without additional features such as tremor or rigidity. BL is defined as the last non-missing assessment measured on or before the first dose date. The percent change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. Percentage of participants meeting the criterion (LS mean on inverse linked scale), odds ratio with 95% CI and p-value comparing against placebo were estimated by Generalized Estimating Equations (GEE) model. Baseline 'off-time', treatment, visit and treatment*visit are included in the model.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  3. Percentage of Participants With a >=2 Hours Reduction in Baseline "Off" Time at Week 4 of the Maintenance Period

    The "off" time is defined as the state in which the participants' symptoms include lack of mobility (bradykinesia) with or without additional features such as tremor or rigidity. BL is defined as the last non-missing assessment measured on or before the first dose date. The percent change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. Percentage of participants meeting the criterion (LS mean on inverse linked scale), odds ratio with 95% CI and p-value comparing against placebo were estimated by Generalized Estimating Equations (GEE) model. Baseline 'off-time', treatment, visit and treatment*visit are included in the model.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  4. Responder Rate According to the Clinical Global Impression-global Improvement (CGI-I) Scale at Week 4 of the Maintenance Period

    The CGI-I scale allows the investigator to rate the participant's total improvement since the beginning of treatment (Baseline). Baseline is defined as the last non-missing assessment measured on or before the first dose date. The scale is rated from 1-7 where 1 = "very much improved", 2 = "much improved", 3 = "minimally improved", 4 = "no change", 5 = "minimally worse, 6 = "much worse", and 7 = "very much worse". The responder rate is defined as the percentage of participants with a score of 1 or 2. The Generalized Estimating Equations (GEE) model was used to determine CGI responder rate with treatment, visit, and treatment by visit interaction included in the model. Only scheduled visits were included.

    Measured: Week 4 of the Maintenance Period (Study Week 17)

  5. Change From Baseline in Absolute Awake Time Spent "on" Without Troublesome Dyskinesia (TD) at Week 4 of the Maintenance Period

    Dyskinesias are involuntary twisting, turning movements caused by medication during "on" time in Parkinson's Disease (PD). TD is defined as those movements that interfere with function and cause meaningful discomfort. Par were asked to record awake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit. The total number of awake hours spent "on" without TD per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent "on" without TD in each 24 hour diary card. The change from BL was calculated by subtracting the BL values from the MP Week 4 values. LS means, 95% CIs and P-values were estimated from Mixed Model Repeated Measures (MMRM). Par with a non-missing efficacy observation at BL and during the MP were analyzed.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  6. Change From Baseline in Absolute Awake Time Spent "on" at Week 4 of the Maintenance Period

    Par were asked to record awake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of awake hours spent "on" per 24-hour period was the average across the 2 diary cards of the sum of the awake hours spent "on" in each 24 hour diary card. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  7. Change From Baseline for Total Sleep Time During the Night Time Hours of Sleep at Week 4 of the Maintenance Period

    Par. were asked to record awake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total sleep hours during the night time hours of sleep was the average across the 2 diary cards of the sum of time (hours) asleep during night time in each 24-hour diary card. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  8. Percent Change From Baseline in Awake Time Spent "Off" at Week 4 of the Maintenance Period

    The "off" state is defined as the state in which the participants' symptoms include lack of mobility (bradykinesia), with or without additional features such as tremor or rigidity. Par. were asked to record awake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of awake hours spent "off" per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent "off" in each 24-hour diary card. The percent change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values divided by BL values multiplied (×) the results with 100. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  9. Percent Change From Baseline in Awake Time Spent "on" Without TD at Week 4 of the Maintenance Period

    Dyskinesias are involuntary twisting, turning movements caused by medication during "on" time in PD. TD is defined as those movements that interfere with function and cause meaningful discomfort. Par. were asked to record awake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of awake hours spent "on" without TD per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent "on" without TD in each 24-hour diary card. The percent change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values divided by BL values × 100. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  10. Percent Change From Baseline in Awake Time Spent "on" at Week 4 of the Maintenance Period

    Par. were asked to recordawake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of awake hours spent "on" per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent "on" in each 24-hour diary card. The percent change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values divided by BL values × 100. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  11. Percent Change From Baseline in Total Sleep Time During the Night Time Hours of Sleep, at Week 4 of the Maintenance Period

    Par. were asked to record awake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total sleep hours during the night time hours of sleep was the average across the 2 diary cards of the sum of time (hours) asleep during night time in each 24-hour diary card. BL is defined as the last non-missing assessment measured on or before the first dose date. The percent change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values divided by BL value × 100. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  12. Change From Baseline in the Percent Awake Time Spent "Off" at Week 4 of the Maintenance Period

    The "off" state is defined as the state in which the participants' symptoms include lack of mobility(bradykinesia), with or without additional features such as tremor or rigidity. Par were asked to record awake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of awake hours spent "off" per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent "off" in each 24-hour diary card. The percentage of awake time spent "off"= Awake time spent "off" divided by (Awake time spent "off" + Awake time spent "on") × 100. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the MP Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  13. Change From Baseline in the Percent Awake Time Spent "on" Without TD at Week 4 of the Maintenance Period

    Dyskinesias are involuntary twisting, turning movements caused by medication during "on" time in PD. TD is defined as those movements that interfere with function and cause meaningful discomfort. Par were asked to record awake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hr diary cards for the 2 days preceding each visit of the study. The total number of awake hr spent "on" without TD per 24-hr period was the average across the 2 diary cards of the sum of awake hr spent "on" without TD in each 24-hr diary card. Percentage of awake time spent "on"without TD= Awake time spent "on" without TD divided by(Awake time spent "on" + Awake time spent "off") × 100. BL is defined as the last non-missing assessment measured on or before the first dose date, change from BL was calculated by subtracting BL values from MP Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  14. Change From Baseline in the Percent Awake Time Spent "on" at Week 4 of the Maintenance Period

    Par. were asked to record awake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of awake hours spent "on" per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent "on" in each 24-hour diary card. The percentage of awake time spent "on"= Awake time spent "on" divided by (Awake time spent "on" + Awake time spent "off") × 100. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  15. Change From Baseline in the Percent of a 24-hour Day Spent "Off" at Week 4 of the Maintenance Period

    The "off" state is defined as the state in which the participants' symptoms include lack of mobility (bradykinesia), with or without additional features such as tremor or rigidity. Par were asked to record awake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of day awake hours spent "off" per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent "off" in each 24-hour diary card. The percentage of 24 hour day spent "off"= awake time spent "off" divided by 24 x 100. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the MP Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  16. Change From Baseline in the Percent of a 24- Hour Day Spent "on" Without TD at Week 4 of the Maintenance Period

    Dyskinesias are involuntary twisting, turning movements caused by medication during "on" time in PD. TD is defined as those movements that interfere with function and cause meaningful discomfort. Par were asked to record awake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hr diary cards for the 2 days preceding each visit. The total number of day awake hr spent "on" without TD per 24-hr period was the average across the 2 diary cards of the sum of awake hours spent "on" without TD in each 24-hour diary card. The percentage of 24 hr day spent "on" without TD= awake time spent "on" without TD divided by 24 × 100. BL is defined as the last non-missing assessment measured on or before the first dose date, change from BL was calculated by subtracting the BL values from the MP Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  17. Change From Baseline in the Percent of a 24-hour Day Spent "on" at Week 4 of the Maintenance Period

    Par. were asked to record awake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total number of day awake hours spent "on" per 24-hour period was the average across the 2 diary cards of the sum of awake hours spent "on" in each 24-hour diary card. The percentage of a 24-hour day spent "on" = Awake time spent "on" divided by 24 × 100. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  18. Change From Baseline in Total Sleep Time During the Night Time Hours of Sleep as a Percentage of a 24-hour Day, at Week 4 of the Maintenance Period

    Par were asked to record awake time "off", awake time "on", TD during awake time "on", or time asleep for all 30 minute time intervals in 24 hour diary cards for the 2 days preceding each visit of the study. The total sleep hours during the night time hours of sleep was the average across the 2 diary cards of the sum of time (hours) asleep during night time in each 24-hour diary card. The percentage of a 24-hour day spent asleep during the night time hours = Total sleep hours during the night time hours of sleep divided by 24 × 100. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  19. Change From Baseline in Unified Parkinson Disease Rating Scale (UPDRS) Motor Score With Participants in an "on" State, at Week 4 of the Maintenance Period

    The UPDRS is a clinician based rating scale used to measure motor impairments and disability. The UPDRS assesses six features of PD impairment. These are evaluated using a combination of data collected by interview and examination of the par.. One of the six features include the Part III-motor examination where scores can range 0 to 108 with par. in an "on" state where the maximum score indicates the worse condition. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  20. Change From Baseline in UPDRS Activities of Daily Living (ADL) Score With Participants in an "on" State, at Week 4 of the Maintenance Period

    The UPDRS Part II is the ADL score and can range from 0 to 52 as determined by the physician. The higher score indicates the worse condition. Test were performed when the par. is in the "on" state of PD. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  21. Change From Baseline in UPDRS ADL Score With Participants in an "Off" State, at Week 4 of the Maintenance Period

    The UPDRS Part II is the ADL score and can range from 0 to 52 as determined by the physician. The higher score indicates the worse condition. Test was performed when the par is in the "off" state of PD. The "off" time is defined as the state in which the participants' symptoms include lack of mobility (bradykinesia) with or without additional features such as tremor or rigidity. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the Maintenance Period Week 4 values. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline and Week 4 of the Maintenance Period (Study Week 17)

  22. Change From Baseline in UPDRS Part I at Week 4 of the Maintenance Period

    The UPDRS Part I scores mentation, behavior and mood as determined by a physician and par. were tested during the "on" phase of PD. This component of the UPDRS is the total score for 4 items (the items 1 to 4 include intellectual impairment, thought disorder, motivation / initiative, and depression) and may have a value ranging from 0 to 16 as determined by a physician. The higher score (16) indicates the maximum score and the worse condition. All 4 items have to be present for a total score to be calculated. If one or more items are missing, the total score for the component would also be missing. BL is defined as the last non-missing assessment measured on or before the first dose date. The change from BL was calculated by subtracting the BL values from the individual post-randomization values. LS means, 95% CIs and P-values were estimated from MMRM.

    Measured: Baseline (BL) and Week 4 of the Maintenance Period (Study Week 17)

  23. Percentage of Participants Withdrawn From the Study Due to Lack of Efficacy

    The percentage of participants who withdrew from the study due to lack of efficacy as defined by either the participant or the investigator is presented here. All participants with a non-missing efficacy observation at Baseline and at least one post-Baseline efficacy assessment at any time during the study were analyzed.

    Measured: From start of study treatment until end of treatment (assessed up to 18 weeks)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 Dec 2011 (estimated)
  2. Study start2 Apr 2012
  3. Primary completion18 Nov 2014
  4. Study completion18 Nov 2014

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
352 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01494532
Sponsor's protocol ID
111569
Acronym
TANDEM-569
Status last verified
Jun 2018
First submitted
1 Dec 2011
Last updated
20 Jun 2018
Data monitoring committee
No
Individual data sharing
Yes: Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing ropinirole/L-dopa in people with Parkinson Disease, run by GlaxoSmithKline at 52 sites in 7 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Jun 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 52 sites in Russia, United States, Argentina, South Korea, Slovakia and 2 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 3 Dec 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline (BL) in Total Awake Time Spent "Off" at Week 4 of Maintenance Period (time frame: Baseline and Week 4 of the Maintenance Period (Study Week 17)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jun 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
TANDEM-569 Clinical Trial NCT01494532 | AzTrials